ExonHit and Allergan expand collaboration

Article

Allergan, Inc and ExonHit Therapeutics have expanded their current drug discovery collaboration until December 2011. The current agreement, focused on finding drug treatments for neurodegenerative diseases and pain as well as ophthalmic targets, was established in 2003 and, following two previous extensions due to success, was due to expire in December 2009.

Allergan, Inc and ExonHit Therapeutics have expanded their current drug discovery collaboration until December 2011. The current agreement, focused on finding drug treatments for neurodegenerative diseases and pain as well as ophthalmic targets, was established in 2003 and, following two previous extensions due to success, was due to expire in December 2009.

The collaboration has been extended to include development of ocular antibody therapeutics through epitope discovery for immune responses. Although no specific financial terms were disclosed, it is understood that Allergan will now provide increased quarterly research funding in place of a single large payment, and that Allergan now has increased sublicensing rights in connection with any compounds discovered.

Of the compounds already identified and developed under the collaboration, EHT/AGN 0001 is completing Phase I testing for pain, and the remaining compounds are in preclinical testing.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.